Neuroprotection beyond neurons: integrated biomarker-based and astroglia- or microglia-targeted approaches to combat neurodegenerative diseases
Cinzia Volonté , Guoku Hu , Christopher A. Shaw , Claudio Viegas Jr. , Joyce Alves dos Santos , Sandra H. Vaz , Ana M. Sebastião , Vladimir J. Balcar , P. David Mozley , Federico Verde , Vincenzo Silani , Fernanda Tibolla Viero , Yong Tang , Henning Ulrich , Rafael Franco
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004136
Neurodegenerative diseases, including Alzheimer’s, Parkinson’s, Huntington’s, and Amyotrophic Lateral Sclerosis, are characterized by multifactorial pathologies that extend beyond neuronal loss to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and glial dysregulation. Despite extensive research, disease-modifying therapies remain elusive, hindered by late diagnosis, limited availability of specific biomarkers, and the persistent dominance of reductionist, single-target strategies. This comprehensive and informative review provides a critical synthesis of integrated neuroprotective strategies, with particular focus on glial mechanisms and biomarker-guided interventions. Therapeutic emphasis is placed on coordinated mechanisms targeting both neurons and non-neuronal cells, such as astrocytes, microglia, and oligodendrocytes. Emerging strategies are reported to include modulation of synaptic plasticity and neurotransmission, delivery of neurotrophic factors, activation of intrinsic cytoprotective pathways (e.g., Nrf2 signaling), restoration of proteostasis, and induction of regeneration via cellular reprogramming. Glial cells are discussed as therapeutic targets involved in inflammation, metabolism, myelination, and neuronal survival. Advances in predictive, preventive, personalized, and participatory (P4) medicine, supported by genomics, multi-omics, imaging, and real-world data, are presented as accelerating biomarker discovery and enabling earlier and more precise stage-specific interventions. Future success in combating neurodegeneration will depend on integrated approaches that combine protective, supportive, and regenerative strategies, appropriate for disease stage and patient profile. By reframing neuroprotection as a systemic, multicellular endeavor, this review highlights the potential to not only extend life expectancy, but also preserve meaningful quality of life in individuals affected by neurodegenerative diseases.
Alzheimer’s disease / Huntington’s disease / Parkinson’s disease / amyotrophic lateral sclerosis / P4 medicine / proteomics / metabolomics
| [1] |
|
| [2] |
Collaborators G2NSD. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024; 23: 344-81. |
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021; 397: 2284-303. |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
Aron L, Ngian ZK, Qiu C, Choi J, Liang M, Drake DM, |
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
Suchowersky O, Armstrong MJ, |
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
Hsiao H, Chen Y, Huang C, Chen C, Hsu Y, Chen H, |
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
Riva N, Domi T, Pozzi L, Lunetta C, Schito P, Spinelli EG, |
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
Feldman EL, Sattler R, Kiernan MC, Goutman SA, Chiò A, Al-Chalabi A. Transforming amyotrophic lateral sclerosis into a liveable disease. Lancet Neurol. 2025; 24: 100-1. |
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
Neupane P, |
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
Goldshtein H, Muhire A, |
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
Nakintu A, Vicario CM, Wang L, Luan S, |
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
Olney JW. Excitotoxicity, apoptosis and neuropsychiatric disorders. Curr Opin Pharmacol. 2003; 3: 101-9. |
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
Allen JW, Ivanova SA, |
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
BRAIN Initiative Cell Census Network (BICCN). A multimodal cell census and atlas of the mammalian primary motor cortex. Nature. 2021; 598: 86-102. |
| [120] |
|
| [121] |
|
| [122] |
Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016; 173: 649-65. |
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
| [141] |
|
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
|
| [148] |
Nomura Y. Neuronal apoptosis and protection: effects of nitric oxide and endoplasmic reticulum-related proteins. Biol Pharm Bull. 2004; 27: 961-3. |
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
|
| [165] |
|
| [166] |
|
| [167] |
Radi R. Oxygen radicals, nitric oxide, and peroxynitrite: Redox pathways in molecular medicine. Proc Natl Acad Sci U S A. 2018; 115: 5839-48. |
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
Butterfield DA. Brain lipid peroxidation and alzheimer disease: Synergy between the Butterfield and Mattson laboratories. Ageing Res Rev. 2020; 64: 101049. |
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
|
| [177] |
|
| [178] |
|
| [179] |
|
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
|
| [196] |
|
| [197] |
|
| [198] |
|
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
|
| [203] |
Lynch MA. Long-term potentiation and memory. Physiol Rev. 2004; 84: 87-136. |
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
|
| [208] |
|
| [209] |
Wu W, Gong X, Qin Z, |
| [210] |
|
| [211] |
|
| [212] |
|
| [213] |
|
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
|
| [218] |
|
| [219] |
|
| [220] |
|
| [221] |
|
| [222] |
|
| [223] |
|
| [224] |
|
| [225] |
|
| [226] |
|
| [227] |
|
| [228] |
|
| [229] |
|
| [230] |
|
| [231] |
|
| [232] |
|
| [233] |
|
| [234] |
|
| [235] |
|
| [236] |
|
| [237] |
|
| [238] |
|
| [239] |
|
| [240] |
|
| [241] |
Sil S, Dagur RS, |
| [242] |
|
| [243] |
Pañeda A, Collantes M, |
| [244] |
|
| [245] |
|
| [246] |
|
| [247] |
|
| [248] |
|
| [249] |
|
| [250] |
|
| [251] |
|
| [252] |
|
| [253] |
|
| [254] |
Wu Q, Zhang T, Chen H, Yu X, Lv J, Liu Y, |
| [255] |
|
| [256] |
|
| [257] |
|
| [258] |
|
| [259] |
|
| [260] |
|
| [261] |
|
| [262] |
|
| [263] |
|
| [264] |
|
| [265] |
Schmidt S, |
| [266] |
|
| [267] |
Ohtake Y, Hayat U, |
| [268] |
|
| [269] |
|
| [270] |
|
| [271] |
|
| [272] |
|
| [273] |
|
| [274] |
|
| [275] |
|
| [276] |
|
| [277] |
|
| [278] |
|
| [279] |
|
| [280] |
|
| [281] |
|
| [282] |
|
| [283] |
|
| [284] |
|
| [285] |
|
| [286] |
|
| [287] |
|
| [288] |
|
| [289] |
|
| [290] |
|
| [291] |
|
| [292] |
|
| [293] |
|
| [294] |
|
| [295] |
|
| [296] |
|
| [297] |
|
| [298] |
Horvat A, Zorec R, |
| [299] |
|
| [300] |
|
| [301] |
Kwak H, Koh W, Kim S, Song K, Shin J, |
| [302] |
|
| [303] |
|
| [304] |
|
| [305] |
|
| [306] |
|
| [307] |
|
| [308] |
|
| [309] |
|
| [310] |
|
| [311] |
|
| [312] |
Schousboe A. Astrocytic Metabolism Focusing on Glutamate Homeostasis: A Short Review Dedicated to Vittorio Gallo. Neurochem Res. 2020; 45: 522-5. |
| [313] |
|
| [314] |
|
| [315] |
|
| [316] |
|
| [317] |
|
| [318] |
|
| [319] |
|
| [320] |
|
| [321] |
|
| [322] |
|
| [323] |
|
| [324] |
Lee J, Chun Y, Han K, Lee J, Woo DH, Lee CJ. Ca(2+) Entry is Required for Mechanical Stimulation-induced ATP Release from Astrocyte. Exp Neurobiol. 2015;24:17-23. |
| [325] |
|
| [326] |
|
| [327] |
|
| [328] |
|
| [329] |
|
| [330] |
|
| [331] |
|
| [332] |
|
| [333] |
|
| [334] |
|
| [335] |
|
| [336] |
|
| [337] |
|
| [338] |
|
| [339] |
|
| [340] |
|
| [341] |
|
| [342] |
|
| [343] |
|
| [344] |
|
| [345] |
|
| [346] |
|
| [347] |
|
| [348] |
Chun H, |
| [349] |
|
| [350] |
|
| [351] |
|
| [352] |
|
| [353] |
|
| [354] |
|
| [355] |
|
| [356] |
|
| [357] |
|
| [358] |
|
| [359] |
|
| [360] |
|
| [361] |
|
| [362] |
|
| [363] |
|
| [364] |
|
| [365] |
|
| [366] |
|
| [367] |
Arnaiz SL, D’Amico G, Paglia N, Arismendi M, Basso N, del Rosario Lores Arnaiz M. Enriched environment, nitric oxide production and synaptic plasticity prevent the aging-dependent impairment of spatial cognition. Mol Aspects Med. 2004; 25: 91-101. |
| [368] |
|
| [369] |
Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001; 65: 1-105. |
| [370] |
|
| [371] |
|
| [372] |
|
| [373] |
|
| [374] |
Jacob CP, |
| [375] |
|
| [376] |
|
| [377] |
|
| [378] |
|
| [379] |
|
| [380] |
Costa-Pinto S, Gonçalves-Ribeiro J, Tedim-Moreira J, Socodato R, Relvas JB, Sebastião AM, et al. Communication defects with astroglia contribute to early impairments in the motor cortex plasticity of SOD1G93Amice. Neurobiol Dis. 2024;193:106435. |
| [381] |
|
| [382] |
|
| [383] |
|
| [384] |
|
| [385] |
|
| [386] |
|
| [387] |
|
| [388] |
|
| [389] |
|
| [390] |
|
| [391] |
Sugiyama K, |
| [392] |
Guo H, Lai L, |
| [393] |
|
| [394] |
|
| [395] |
Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003; 53: 423-6. |
| [396] |
|
| [397] |
|
| [398] |
|
| [399] |
|
| [400] |
|
| [401] |
|
| [402] |
|
| [403] |
|
| [404] |
|
| [405] |
|
| [406] |
|
| [407] |
|
| [408] |
|
| [409] |
|
| [410] |
|
| [411] |
|
| [412] |
|
| [413] |
|
| [414] |
|
| [415] |
|
| [416] |
|
| [417] |
|
| [418] |
|
| [419] |
|
| [420] |
|
| [421] |
Illes P. P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases. Int J Mol Sci. 2020; 21: 5996. |
| [422] |
|
| [423] |
|
| [424] |
|
| [425] |
|
| [426] |
|
| [427] |
|
| [428] |
|
| [429] |
|
| [430] |
|
| [431] |
Yoshida Y, Une F, Utatsu Y, Nomoto M, Furukawa Y, Maruyama Y, |
| [432] |
Vincenzi F, Corciulo C, Targa M, Casetta I, Gentile M, Granieri E, |
| [433] |
|
| [434] |
|
| [435] |
|
| [436] |
|
| [437] |
|
| [438] |
Hou X, Li Y, Huang Y, Zhao H, |
| [439] |
|
| [440] |
|
| [441] |
|
| [442] |
|
| [443] |
|
| [444] |
|
| [445] |
|
| [446] |
|
| [447] |
|
| [448] |
|
| [449] |
|
| [450] |
|
| [451] |
|
| [452] |
|
| [453] |
|
| [454] |
|
| [455] |
|
| [456] |
|
| [457] |
|
| [458] |
|
| [459] |
|
| [460] |
|
| [461] |
|
| [462] |
|
| [463] |
|
| [464] |
|
| [465] |
|
| [466] |
|
| [467] |
|
| [468] |
|
| [469] |
|
| [470] |
|
| [471] |
|
| [472] |
|
| [473] |
|
| [474] |
|
| [475] |
|
| [476] |
|
| [477] |
|
| [478] |
|
| [479] |
|
| [480] |
|
| [481] |
|
| [482] |
|
| [483] |
|
| [484] |
|
| [485] |
|
| [486] |
|
| [487] |
|
| [488] |
|
| [489] |
|
| [490] |
|
| [491] |
|
| [492] |
|
| [493] |
Masuda T, Sankowski R, Staszewski O, Böttcher C, Amann L, Sagar, |
| [494] |
|
| [495] |
|
| [496] |
|
| [497] |
|
| [498] |
|
| [499] |
Goedert M. Alzheimer’s and Parkinson’s diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015; 349: 1255555. |
| [500] |
|
| [501] |
|
| [502] |
|
| [503] |
|
| [504] |
|
| [505] |
|
| [506] |
|
| [507] |
|
| [508] |
Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, |
| [509] |
|
| [510] |
Oh ES. Dementia. Ann Intern Med. 2024; 177: ITC161-76. |
| [511] |
|
| [512] |
|
| [513] |
|
| [514] |
|
| [515] |
|
| [516] |
|
| [517] |
|
| [518] |
|
| [519] |
|
| [520] |
|
| [521] |
|
| [522] |
|
| [523] |
Šerý O, Janoutová J, Ewerlingová L, Hálová A, Lochman J, Janout V, |
| [524] |
|
| [525] |
Šerý O, Zeman T, Sheardová K, Vyhnálek M, Marková H, Laczó J, |
| [526] |
|
| [527] |
|
| [528] |
|
| [529] |
|
| [530] |
|
| [531] |
|
| [532] |
|
| [533] |
|
| [534] |
|
| [535] |
Stefanini E, Iglesias A, Serrano-Marín J, Sánchez-Navés J, |
| [536] |
|
| [537] |
|
| [538] |
|
| [539] |
|
| [540] |
|
| [541] |
Biomarkers Inventory - ESR | European Society of Radiology [Internet]. European Society of Radiology; c2025 [cited 2025 Dec 10]. Available from: https://www.myesr.org/research/biomarkers-inventory/ |
| [542] |
|
| [543] |
|
| [544] |
|
| [545] |
|
| [546] |
|
| [547] |
|
| [548] |
|
| [549] |
|
| [550] |
|
| [551] |
Gibbons CH, Freeman R, Bellaire B, Adler CH, Moore D, Levine T. Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies. Biomark Med. 2022; 16: 499-509. |
| [552] |
|
| [553] |
|
| [554] |
|
| [555] |
|
| [556] |
|
| [557] |
|
| [558] |
|
| [559] |
|
| [560] |
|
| [561] |
|
| [562] |
|
| [563] |
|
| [564] |
|
| [565] |
|
| [566] |
Casson RJ, Chidlow G, Ebneter A, Wood JPM, Crowston J, Goldberg I. Translational neuroprotection research in glaucoma: a review of definitions and principles. Clin Exp Ophthalmol. 2012; 40: 350-7. |
| [567] |
|
| [568] |
Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, |
| [569] |
Pound P, |
| [570] |
Macleod MR, Lawson McLean A, Kyriakopoulou A, Serghiou S, de Wilde A, Sherratt N, |
| [571] |
|
| [572] |
|
| [573] |
|
| [574] |
|
| [575] |
|
| [576] |
|
| [577] |
|
| [578] |
|
| [579] |
|
| [580] |
Gaetani L, Blennow K, Calabresi P, Filippo MD, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019; 90: 870-81. |
| [581] |
|
| [582] |
|
| [583] |
Abukuri DN. Novel Biomarkers for Alzheimer's Disease: Plasma Neurofilament Light and Cerebrospinal Fluid. Int J Alzheimers Dis. 2016; 2016: 6668159. |
| [584] |
|
| [585] |
|
| [586] |
|
| [587] |
|
| [588] |
|
| [589] |
|
| [590] |
|
| [591] |
|
| [592] |
|
| [593] |
|
| [594] |
|
| [595] |
|
| [596] |
|
| [597] |
|
| [598] |
|
| [599] |
|
| [600] |
Zhao G, Zhang H, Xu Y, |
| [601] |
|
| [602] |
|
| [603] |
|
| [604] |
|
| [605] |
Huang G, Chen X, |
| [606] |
|
| [607] |
|
| [608] |
|
| [609] |
|
| [610] |
|
| [611] |
|
| [612] |
Neurotechnology and neurorights - Privacy’s last frontier [Internet]. European Parliament; [cited 2025 Jul 17]. Available from: https://www.europarl.europa.eu/thinktank/de/events/details/neurotechnology-and-neurorights-privacy-/20231019WKS05721 |
| [613] |
|
| [614] |
|
| [615] |
|
| [616] |
|
| [617] |
|
| [618] |
|
| [619] |
|
| [620] |
|
| [621] |
Yang EJ. The Emerging Role of the Brain-Gut Axis in Amyotrophic Lateral Sclerosis: Pathogenesis, Mechanisms, and Therapeutic Perspectives. Int J Mol Sci. 2025; 26: 8419. |
| [622] |
|
| [623] |
|
| [624] |
|
| [625] |
|
| [626] |
|
| [627] |
|
| [628] |
|
| [629] |
Barnes LL. Biomarkers for Alzheimer Dementia in Diverse Racial and Ethnic Minorities-A Public Health Priority. JAMA Neurol. 2019; 76: 251-3. |
| [630] |
|
| [631] |
Kolbe A. HHS Actions to Enhance Diversity in Clinical Research: Issue Brief. Washington (DC): Office of the Assistant Secretary for Planning and Evaluation (ASPE); 2024. |
| [632] |
Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. |
| [633] |
|
| [634] |
|
| [635] |
Pallmann P, |
| [636] |
Hammouri H, Salman M, Ali M, |
| [637] |
Molla G, |
| [638] |
|
| [639] |
Iacovitti L. Neuroprotection: Basic mechanisms and translational potential. Brain Res. 2015; 1628: 245-6. |
/
| 〈 |
|
〉 |